Molecular determinants of clinical outcomes with pembrolizumab versus paclitaxel in a randomized, open-label, phase III trial in patients with gastroesophageal adenocarcinoma

Shitara, K.; ÖZGÜROĞLU, Mustafa; Bang, Y-J; Di Bartolomeo, M.; Mandala, M.; Ryu, M-H; Caglevic, C.; Chung, H.; Muro, K.; Van Cutsem, E.; Kobie, J.; Cristescu, R.; Aurora-Garg, D.; Lu, J.; Shih, C-S; Adelberg, D.; Cao, Z.; Fuchs, C.

doi:10.1016/j.annonc.2021.05.803

Molecular determinants of clinical outcomes with pembrolizumab versus paclitaxel in a randomized, open-label, phase III trial in patients with gastroesophageal adenocarcinoma

Shitara K., ÖZGÜROĞLU M., Bang Y., Di Bartolomeo M., Mandala M., Ryu M., ...Daha Fazla

ANNALS OF ONCOLOGY, cilt.32, sa.9, ss.1127-1136, 2021 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 32 Sayı: 9
Basım Tarihi: 2021
Doi Numarası: 10.1016/j.annonc.2021.05.803
Dergi Adı: ANNALS OF ONCOLOGY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, PASCAL, CAB Abstracts, EMBASE, MEDLINE
Sayfa Sayıları: ss.1127-1136
Anahtar Kelimeler: pembrolizumab, chemotherapy, tumor mutational burden, gastroesophageal adenocarcinoma, gastric cancer, TUMOR MUTATIONAL BURDEN, CTLA-4 BLOCKADE, PD-1 BLOCKADE, BENEFIT, CHEMO
İstanbul Üniversitesi Adresli: Hayır

Özet

Background: In the phase III KEYNOTE-061 trial (NCT02370498), pembrolizumab did not significantly improve overall survival versus paclitaxel as second-line therapy for gastric/gastroesophageal junction (GEJ) adenocarcinoma with programmed death-ligand 1 (PD-L1) combined positive score (CPS) >= 1 tumors. The association of tissue tumor mutational burden (tTMB) status and clinical outcomes was determined, including the relationship with CPS and microsatellite instability-high (MSI-H) status.